Quoin pharmaceuticals announces fda clearance to initiate new qrx003 netherton syndrome clinical study

Ashburn, va., dec. 19, 2024 (globe newswire) -- quoin pharmaceuticals ltd. (nasdaq: qnrx) (the “company” or “quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces fda clearance to initiate a new additional netherton syndrome (ns) clinical study for qrx003. qrx003 is a topical lotion that contains a broad-spectrum serine protease inhibitor designed to target the kallikreins in the skin responsible for the excessive skin shedding associated with this disease.
QNRX Ratings Summary
QNRX Quant Ranking